James C. Clemmer Buys 20,000 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer acquired 20,000 shares of the company’s stock in a transaction on Monday, October 7th. The shares were bought at an average cost of $6.03 per share, with a total value of $120,600.00. Following the acquisition, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

AngioDynamics Stock Performance

ANGO traded down $0.22 during trading on Tuesday, hitting $5.88. The stock had a trading volume of 940,610 shares, compared to its average volume of 527,133. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $8.25. The stock has a 50 day simple moving average of $7.41 and a two-hundred day simple moving average of $6.65. The company has a market capitalization of $235.52 million, a PE ratio of -1.21 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The business’s revenue for the quarter was down 14.2% compared to the same quarter last year. On average, equities research analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ANGO shares. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a report on Friday. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP lifted its position in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares during the period. Mackenzie Financial Corp acquired a new position in AngioDynamics during the second quarter valued at $80,000. SG Americas Securities LLC acquired a new position in AngioDynamics during the third quarter valued at $103,000. AE Wealth Management LLC acquired a new position in AngioDynamics during the second quarter valued at $87,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in AngioDynamics by 44.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 4,780 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.